<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02269904</url>
  </required_header>
  <id_info>
    <org_study_id>Sinofuan01</org_study_id>
    <nct_id>NCT02269904</nct_id>
  </id_info>
  <brief_title>Fluorouracil Implants Used for Intraperitoneal Chemotherapy During Operation for Treatment of Phase III Gastric Cancer.</brief_title>
  <official_title>Fluorouracil Implants（SinoFuan®）Used for Intraperitoneal Chemotherapy During Operation for Intraperitoneal Chemotherapy During Operation for Treatment of Phase III Gastric Cancer, Randomized, Controlled, Multicentres Open Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Simcere Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Simcere Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SinoFuan is a kind of Fluorouracil Implants for intraperitoneal chemotherapy during operation
      for treatment of gastric cancer. The indication has bee approved by Chinese FDA. The study is
      a post-marketing study. The subjects will be divided into two groups (Group A and Group B ).
      The subject in Group A will receive D2 radical gastrectomy(R0),Sinofuan during operation and
      6 cycles of Xelox adjuvant chemotherapy.The subject in Group B will receive D2 radical
      gastrectomy(R0),and 6 cycles of Xelox adjuvant chemotherapy. The subject's benefits from
      SinoFuan will be analyzed through comparing 3 years DFS of two groups.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DFS (Disease Free Survival)</measure>
    <time_frame>3 year</time_frame>
    <description>During 3 years of monitoring period, any cancer relapse will be recorded</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse event</measure>
    <time_frame>3 years</time_frame>
    <description>During 3 years of monitoring period, any AEs will be recorded</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>DSF</condition>
  <arm_group>
    <arm_group_label>Fluorouracil Implants and Xelox regimes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluorouracil Implants: 800mg, implanted in the abdominal cavity during operation.
Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xelox regimes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil Implants</intervention_name>
    <description>Fluorouracil Implants: 800mg, implanted in the abdominal cavity during operation.</description>
    <arm_group_label>Fluorouracil Implants and Xelox regimes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xelox regimes</intervention_name>
    <description>Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished.</description>
    <arm_group_label>Fluorouracil Implants and Xelox regimes</arm_group_label>
    <arm_group_label>Xelox regimes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. primary gastric cancer, Phase III

          2. D2 radical gastrectomy(R0)

          3. 18 year old or above

          4. KPS≥70%；

          5. suitable hematologic function: ANC≥1.5×109/L, PLC≥80×109/L

          6. suitable liver function: Total bilirubin≤1.5×normal ULN, AST and ALT≤2.5×normal ULN.

          7. suitable renal function: Cr≤1.5×normal ULN,or Ccr≥50 ml/min 8 .for the female subject,
             pregnancy test must be negative in 27 hours before enrollment .

        9. the authorized ICF must be signed

        Exclusion Criteria:

          1. non-initial gastric cancer；

          2. having the other uncontrolled diseases.

          3. obvious loss of weight ( more than 10% within 6 weeks )

          4. the female in pregnancy or feeding.

          5. contraindication to study drug

          6. participating in other clinical trial and at the time of treatment period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yan Xu, Doctor</last_name>
    <phone>13204032770</phone>
    <email>xyab@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bo Li, Doctor</last_name>
    <phone>13940018765</phone>
    <email>ydyyllwyh2010@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Heilongjiang Cancer Hospital</name>
      <address>
        <city>Harebin</city>
        <state>Heilongjiang</state>
        <zip>150000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunfeng Li, Doctor</last_name>
      <phone>18745787187</phone>
      <email>lichunfeng007@163.com</email>
    </contact>
    <investigator>
      <last_name>Yingwei Xue, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2014</study_first_submitted>
  <study_first_submitted_qc>October 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2014</study_first_posted>
  <last_update_submitted>October 17, 2014</last_update_submitted>
  <last_update_submitted_qc>October 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

